Clinical observation on prevention of postpartum depression by dexmedetomidine during painless delivery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059826

Enrollment

Unknown

Registered

2022-05-12

Start date

2022-05-12

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum depression

Interventions

Group S:0.1% ropivacaine 2mg lumbar anesthesia, then ropivacaine 100mg combined with sufentanil 50µg diluted to 100mL with normal saline for epidural pump

Group C:0.1% ropivacaine 2mg lumbar anesthesia, then ropivacaine 100mg combined with sufentanil 50µg diluted to 100mL with normal saline for epidural pump

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. ASA I-II; 2. Normal mental state; 3. Single fetus; 4. Normal fetal development.

Exclusion criteria

Exclusion criteria: 1. Sinus syndrome, bradycardia; 2. Contraindications of spinal anesthesia and obstetrics.

Design outcomes

Primary

Measure	Time frame
Incidence and severity of postpartum depression (postpartum 1,6 weeks);	—

Secondary

Measure	Time frame
Vital signs observation (MAP, HR, SpO2);Satisfaction with pain treatment; Pain level relief/management meets maternal pain relief expectations;Duration of labor;Apgar scores 1 and 5 minutes after birth;Analgesic and sedative effect;	—

Countries

China

Contacts

Public ContactZhang Erfei

The Affiliated Hospital of Yan'an University

zhangerfei09@126.com+86 13891170975

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026